Sestina Bio

Sestina Bio is a biotechnology company focused on developing innovative solutions for bio-manufacturing, utilizing advanced techniques to optimize microbial strains for various commercial applications. Founded in 2020, Sestina Bio operates out of Pleasanton, US, specializing in biomanufacturing technologies. The company was established by Bill Colston and Ted Tarasow, with Colston currently serving as CEO. Sestina Bio was acquired in January 2023 by Inscripta, Inc.

, a portfolio company of various investment firms, marking a significant pivot in its operational strategy. Sestina Bio specializes in advanced biomanufacturing solutions, employing its proprietary Lean Bioengineering™ approach. The core offering includes the GenoScaler™, which utilizes Directed Evolution, CRISPR+, and Machine Learning to enhance microbial strains for commercial use, addressing challenges in pharmaceuticals and agriculture. Their services cater to biotech firms, research institutions, and companies in the food and beverage sector, with a global reach including North America, Europe, and parts of Asia.

Sestina Bio generates revenue through direct sales and strategic partnerships within the biotechnology sector. Revenue streams include licensing fees, tailored project contracts, and subscription models for ongoing services. Pricing is based on project scope and client customization, positioning their products to meet demands for sustainable biomanufactured solutions. Following the acquisition in January 2023, Sestina Bio intends to leverage Inscripta's resources to foster the development of bio-manufactured products aimed at various industrial applications.

The company is exploring entry into new markets including Asia and Europe by 2024. The recent funding will support these initiatives, facilitating the design and distribution of innovative biomanufacturing solutions across multiple sectors.